About Circassia Pharmaceuticals
Circassia Pharmaceuticals is a company based in Oxford (United Kingdom) founded in 2006 by Charles Swingland. Circassia Pharmaceuticals has raised $156.6 million across 5 funding rounds from investors including Goldman Sachs, Invesco Perpetual and Imperial Innovations. The company has 128 employees as of December 31, 2021. Circassia Pharmaceuticals has completed 1 acquisition, including Prosonix. Circassia Pharmaceuticals offers products and services including NIOX Device and FeNO by NIOX Range. Circassia Pharmaceuticals operates in a competitive market with competitors including BeiGene, Serum Institute of India, BioNTech, Vir Biotechnology and Cidara Therapeutics, among others.
- Headquarter Oxford, United Kingdom
- Employees 128 as on 31 Dec, 2021
- Founders Charles Swingland
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Circassia Pharmaceuticals Plc
-
Annual Revenue
$29.58 M (USD)126as on Dec 31, 2018
-
Net Profit
-$42.36 M (USD)27as on Dec 31, 2018
-
EBITDA
Not available
-
Total Equity Funding
$156.6 M (USD)
in 5 rounds
-
Latest Funding Round
$6.21 M (USD), Post-IPO
Jun 02, 2020
-
Investors
Goldman Sachs
& 5 more
-
Employee Count
128
as on Dec 31, 2021
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Circassia Pharmaceuticals
Circassia Pharmaceuticals is a publicly listed company on the LSE with ticker symbol NIOX in UK, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Circassia Pharmaceuticals
Circassia Pharmaceuticals offers a comprehensive portfolio of products and services, including NIOX Device and FeNO by NIOX Range.
Measures FeNO for accurate asthma diagnosis and monitoring.
Supports airway inflammation assessment in asthma care.
People of Circassia Pharmaceuticals
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Circassia Pharmaceuticals
Circassia Pharmaceuticals has successfully raised a total of $156.6M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $6.21 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Circassia Pharmaceuticals
Circassia Pharmaceuticals has secured backing from 6 investors, including angel, institutional, and venture fund investors. Prominent investors backing the company include Goldman Sachs, Invesco Perpetual and Imperial Innovations.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in startups are focused on Europe and the US.
|
Locked | Locked | Locked | |
|
Investment banking services are delivered across multiple financial sectors.
|
Locked | Locked | Locked | |
|
Diversified investment management services are provided globally.
|
Locked | Locked | Locked |
Investor details for Circassia Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Circassia Pharmaceuticals
Circassia Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Prosonix.
Investment portfolio details for Circassia Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Develops inhaled respiratory medicines.
|
Locked | Locked | 2006 | Locked |
Complete acquisition details for Circassia Pharmaceuticals
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Circassia Pharmaceuticals
Detailed financials for Circassia Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Circassia Pharmaceuticals Comparisons
Peer comparison for Circassia Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Circassia Pharmaceuticals
Circassia Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BeiGene, Serum Institute of India, BioNTech, Vir Biotechnology and Cidara Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Vaccines and immuno-biological drugs for infectious diseases are manufactured.
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of infectious diseases
|
|
| Locked | Locked | Locked |
Novel anti-infectives for bacterial and fungal infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutic proteins are developed for autoimmune and allergic disease treatment.
|
Detailed competitors of Circassia Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Circassia Pharmaceuticals
Complete news archive for Circassia Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Circassia Pharmaceuticals
Circassia Pharmaceuticals was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Circassia Pharmaceuticals is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Circassia Pharmaceuticals is a funded company, having raised a total of $156.6M across 5 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Circassia Pharmaceuticals is 128.
Annual revenue of Circassia Pharmaceuticals is $29.58M as on Dec 31, 2018.
Circassia is focused on developing devices for treatment of allergy and respiratory disease. The company has developed NIOX for asthma management and Tudorza to treat chronic obstructive pulmonary disease. The next-generation immunotherapy technology is in phase III testing for cat allergy and is the first in a new class of treatments, Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs). Three other SPIREs, targeting house dust mite, ragweed and grass allergies, have completed clinical proof-of-concept phase IIb studies. Circassia has also developed FlixotideFlovent substitute and SeretideAdvair substitute. The Company is also developing a number of COPD of treatments, Duaklir US, Spiriva substitute, LABALAMA formulation and COPD therapy formulation.
Circassia Pharmaceuticals's top competitors include BeiGene, BioNTech and Decibel Therapeutics.
Circassia Pharmaceuticals offers NIOX Device and FeNO by NIOX Range.
Yes, Circassia Pharmaceuticals is publicly traded on LSE under the ticker symbol NIOX.
Circassia Pharmaceuticals has made 1 acquisition, including Prosonix.
Circassia Pharmaceuticals has 6 investors. Key investors include Goldman Sachs, Invesco Perpetual, Imperial Innovations, Richard Griffiths, and Lansdowne Partners.
The ticker symbol of Circassia Pharmaceuticals is NIOX on LSE.